Advertisment
The complained about advertisement was a TikTok on the influencer’s own account. The influencer was seen in medium shot with packets of the advertises’ product.
The influencer stated: –
‘Okay girls, I’ve gotten so many questions about the drink. I drink every single day, and it is the FemFuelz’s Gut Balance. I’ve been taking the FemFuelz’s Gut Balance for about six months now, and I swear to God there is not a day I will go without taking it.
Ever since taking it, I’ve noticed it has helped so much with my bloating, my overall energy levels, and as well my skin. It’s really helped my skin, which I’m obsessed with. It also tastes insane.
Like, it’s so easy to drink. I heard they say a healthy gut, a healthy body, and I genuinely could not agree with that statement more. So yeah girls, if you suffer with bloating, maybe you need a little boost in your energy levels, or just want an overall healthy gut, then the FemFuelz’s Gut Balance is something that you need.’
Complaint
The complainant considered that the claim in the advertisement that the product had helped with bloating was misleading and dangerous as they believed that bloating was a medical condition that required medical advice.
Response
Advertisers’ Response:
The advertisers responded that the influencer who posted the video stated that they had been taking the product for about 6 months and that they found it helped so much with their bloating, energy levels, and that they had felt it had helped their skin. The advertisers said that they would never stand over an advertisement that exaggerated the potential benefits of their product and that the complained about advertisement did not exaggerate the benefits. They said that this was a personal testimony regarding the product which contained prebiotics, probiotics, and an ingredient called ‘Wellmune’.
The advertisers confirmed that the product depicted was ‘Gut Balance’ which they said was designed and formulated with various ingredients that aimed to nurture a healthy gut. The advertisers said that they held the evidence to support this.
The advertisers sent two links. One linked to a study entitled The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. The other linked to information on the aforementioned ingredient ‘Wellmune’.
The advertisers referred to the section of the study The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study that they believe supported the claims of their advertising. They quoted the following section: –
‘3.1.1. Primary outcome parameters.
3.1.1.1. GSRS gas and bloating (ingestion) subscale score
The GSRS indigestion subscale score, which includes abdominal distension, borborygmi, burping, and flatulence, changed significantly in the B coagulans group [8.91 ± 2.5–3.06 ± 1.98; P < .001; (N = 33)] when compared to placebo [9.42 ± 2.2–8.33 ± 4.22; p 0.11;(N = 33)] at the end of the study. In addition, the mean change from screening to final visit was significant in the B coagulans group (−5.85) in comparison to the placebo (−1.09), P < .001 (Table 2). A significant reduction was observed in bloating scores 3.28 ± 1.22 to 1.09 ± 0.97, P < .001, compared to 3.42 ± 0.97 to 2.94 ± 1.52, P = NS in placebo. The difference of −2.28 in B coagulans versus −0.66 in placebo was significant (P = .003). Similarly, the Burping (2.94 ± 1.37–1.03 ± 0.84) and Flatus (2.65 ± 1.16–0.91 ± 0.76) scores also decreased significantly’
The advertisers said that it was clear from the above that the group that ingested the active ingredient reported less bloating than the placebo group.
They also quoted an extract which read: –
“Gas and bloating symptoms are common signs of gastrointestinal disorders affecting a larger population. Bacillus coagulans MTCC 5856 at 2 billion CFU per day was significantly effective in alleviating the symptoms of gas and bloating in patients in the absence of other functional gastrointestinal disorders. Therefore, it can be concluded that Bacillus coagulans MTCC 5856 supplementation may be an effective and safe approach to reduce the symptoms of gastrointestinal symptoms in adults with abdominal gas and distension.”
The advertisers reiterated the alleged benefits of Wellmune:-
‘Support general immune health
Maintain overall physical health
Help the body adapt to the effects of stress
Promote healthy energy levels and mental clarity’
They also linked to information about Wellmune. This information was about studies into the effects of baker’s yeast β-glucan (which is what Wellmune was comprised of). There was also a bibliography provided.
The advertisers also attached customer reviews for the product.
Influencer’s Response:
The influencer’s agent responded confirming that the influencer was a user of the product and that her testimony regarding the product and ‘de-bloating’ was based on her lived experience. The agent claimed that this was consistent with the feedback that they had received from over 500 ‘real customers’. They said that on their own review of the content they were confident that it had not breached any advertising codes or guidelines.
The agent attached customer reviews that they said echoed the claims made by the influencer.
Further Information:
The ingredients for ‘Gut Balance’ were as follows: –
Ingredients: –
Chicory Root Fibre, Flavour (Sulphites), Citric Acid, Wellmune Blend® [Yeast (Saccharomyces Cerevisiae) Beta Glucans, Zinc Gluconate], Anti-caking Agent (Silicon Dioxide), Colour (Beetroot Powder), Lactospore® Bacillus Coagulans, Sweetener (Steviol Glycosides).
EU Register of Health Claims
The ASA Executive consulted the EU Register for Health claims and noted that none of the ingredients listed had authorised health claims.
FSAI Query
A query was put to the FSAI regarding bloating. They responded: –
“While reference to bloating in isolation may not be claiming to treat or prevent a disease and/or medical condition, if this is referred to in the context of a medical condition such as IBS this would be considered a non-compliance under article 7 (3) of Regulation 1169/2011 ‘food information shall not attribute to any food the property of preventing, treating or curing a human disease, nor refer to such properties’.
However, an EFSA scientific opinion considered the reduction of bloating, flatulence, or excessive intestinal gas accumulation to be a beneficial physiological effect, meaning such effects can qualify as health claims under Regulation (EC) No 1924/2006, provided that a cause-and-effect relationship has been adequately demonstrated. Please see the footnoted link to the EFSA opinion.
To date there have been no authorised health claims in relation to such health effects including ‘bloating’. There are a number of non-authorised health claims on the EU register in relation to bloating/intestinal discomfort/ flatulence reduction therefore such references to these claims would be unauthorised. They advised that Regulation (EC) No 1924/2006 only applied to nutrition and health claims made in commercial communications, whether in the labelling, presentation or advertising of foods to be delivered as such to the final consumer.”
https://pmc.ncbi.nlm.nih.gov/articles/PMC9982755/
https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2011.2037
Conclusion
Complaint Upheld
The Complaints Council considered the detail of the complaint and the advertisers’ response.
The Council noted that the claim made in the advertising was a health claim. They considered the requirement of the Code that only health claims listed as authorised in the EU Register, or claims that would have the same meaning to the consumer, may be used in marketing communications (S. 8.8) and noted the information provided by the advertisers
The Council noted from the ASA Executive’s review of the EU Register that product ingredients had no associated authorised health claims.
The Council also considered the information provided by the FSAI that there had been no authorised health claims in relation ‘bloating’.
In the light of the above, the Council considered that the advertising was in breach of Sections 8.8, 8.9 and 8.11 of the Code.
Action Required:
The claim made within the advertising should not be used unless it is evidenced by an authorised health claim.